PDCD1 and neoplasm: Given progression of this tumor through anti-PD-1 immunotherapy and previous findings suggesting a predictive significance of the immune status at the invasive tumor margin19, we next compared tumor regions having either a high or low immune cell content as measured by a pan-leukocyte stain (CD45-LCA) on IHC (Supplementary Fig. 1).